Gamma-irradiation induces HER-2/neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab

International Journal of Radiation Biology

Volumn 89, Issue 5, 2013, Pages 319-325

  Voutsas, Ioannis F ^a   Mahaira, Louisa G ^a   Fotopoulou, Katerina ^b   Kapranos, Nikiforos ^c   Reclos, John G ^a   Gritzapis, Angelos D ^a   Papamichail, Michail ^a   Perez, Sonia A ^a   Baxevanis, Constantin N ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b Ygeia Hospital   (Greece)

^c Mitera Hospital   (Greece)

Author keywords

Cellular radiobiology; Gamma irradiation; HER 2 neu; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CHROMOSOME 17; CONTROLLED STUDY; DRUG SENSITIVITY; FLUORESCENCE; FLUORESCENCE IN SITU HYBRIDIZATION; GAMMA IRRADIATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NATURAL KILLER CELL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; GAMMA RAYS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2;

EID: 84877289520     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.3109/09553002.2013.765617     Document Type: Article

References (20)

1. Ahmed KM, Li JJ . 2008. NF-kappa B-mediated adaptive resistance to ionizing radiation. Free Radical Biology & Medicine 44: 1- 13
2. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP, Kraus MH . 1995. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas . Oncogene 10 : 1813 - 1821
3. Cao N, Li S, Wang Z, Ahmed KM, Degnan ME, Fan M, Dynlacht JR, Li JJ . 2009 . NF-kappaB-mediated HER2 overexpression in radiationadaptive resistance . Radiation Research 171: 9- 21
4. Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, Baselga J, Caligiuri MA . 2001. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neupositive breast cancer cells . European Journal of Immunology 31 : 3016 - 3025
5. Clynes RA, Towers TL, Presta LG, Ravetch JV . 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets . Nature Medicine 6 : 443 - 446
6. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE . 2003 . The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation . Proceedings of the National Academy of Sciences 100 : 8933 - 8938
7. Jones KL, Buzdar AU . 2009. Evolving novel anti-HER2 strategies . The Lancet Oncology 10 : 1179 - 1187
8. Kaufman PA, Broadwater G, Lezon-Geyda K, Dressler LG, Berry D, Friedman P, Winer EP, Hudis C, Ellis MJ, Seidman AD, Harris LN . 2007 . CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) effi cacy in CALGB 9840, paclitaxel (P) with or without T in HER2 - and HER2- metastatic breast cancer (MBC) . Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 25 : 1009
9. Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE . 2006 . Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer . Annals of Surgical Oncology 13 : 1085 - 1098
10. Nahta R, Esteva FJ . 2003. HER-2-targeted therapy: Lessons learned and future directions . Clinical Cancer Research 9 : 5078 - 5084
11. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ . 1997. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells . Oncogene 15 : 537 - 547
12. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J . 2006 Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy . The Journal of Experimental Medicine 203 : 1259 - 1271
13. Schieven GL, Kirihara JM, Myers DE, Ledbetter JA, Uckun FM . 1993. Reactive oxygen intermediates activate NF-kappa B in a tyrosine kinase-dependent mechanism and in combination with vanadate activate the p56lck and p59fyn tyrosine kinases in human lymphocytes . Blood 82 : 1212 - 1220
14. Siegel PM, Ryan ED, Cardiff RD, Muller WJ . 1999 . Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: Implications for human breast cancer . The EMBO Journal 18 : 2149 - 2164
15. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL . 1987 . Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene . Science 235 : 177 - 182
16. Sotiriadou NN, Perez SA, Gritzapis AD, Mahaira LG, Salagianni M, Baxevanis CN, Papamichail M . 2005. Beneficial effect of short-term exposure of human NK cells to IL15/IL12 and IL15/IL18 on cell apoptosis and function . Cellular Immunology 234 : 67 - 75
17. Spector NL, Blackwell KL . 2009. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer . Journal of Clinical Oncology 27 : 5838 - 5847
18. Tan M, Yao J, Yu D . 1997 . Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities . Cancer Research 57 : 1199 - 1205
19. Vranic S, Teruya B, Repertinger S, Ulmer P, Hagenkord J, Gatalica Z . 2011 . Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17 . Cancer 117 : 48 - 53
20. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G . 2008 . Immunological aspects of cancer chemotherapy. Nature Reviews . Immunology 8 : 59 - 73